ThomasMCosgriffMDFACP

Oncology • Metairie, LA

Cancer Care of Louisiana

Join to view full profile

Dr. Cosgriff is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Cosgriff's full profile

Already have an account?

Office
4204 Houma Blvd
Fl 2
Metairie, LA 70006
Phone+1 504-883-2960

Fax+1 504-883-2967
Is this information wrong?

Education & Training

University of Utah HealthFellowship, Hematology and Medical Oncology, 1976 - 1978
San Antonio Uniformed Services Health Education ConsortiumResidency, Internal Medicine, 1973 - 1975
University at BuffaloInternship, Internal Medicine, 1970 - 1971
University of Minnesota Medical SchoolClass of 1970

Certifications & Licensure

CA State Medical License 1972 - 2025
LA State Medical License 1993 - 2024
CO State Medical License 1990 - 2023
MN State Medical License 1971 - 2022
MD State Medical License 1978 - 1992
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hospice and Palliative Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura Start of enrollment: 2001 Sep 01
Unknown status
Phase 2
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi Start of enrollment: 2012 Oct 03
Terminated
Phase 3
A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. Start of enrollment: 2013 Feb 26
Completed
Phase 2
Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study. Start of enrollment: 2013 May 14
Completed
Phase 4
Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma Start of enrollment: 2013 Dec 13
Active, not recruiting
Phase 3
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) Start of enrollment: 2014 Mar 27
Completed
Phase 3
Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) Start of enrollment: 2014 May 29
Completed
Phase 3
Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox. Start of enrollment: 2014 Sep 11
Terminated
Phase 2
Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer. Start of enrollment: 2021 Feb 11
Terminated
Phase 2, Phase 3
Join now to see all

Publications & Presentations

PubMed

13 citations
Erratum: Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everoli...
Jennifer J. Knox, Carlos H. Barrios, Tae Min Kim, Thomas Cosgriff, Vichien Srimuninnimit, K. Pittman, Roberto Sabbatini, Sun Young Rha, Thomas W. Flaig, Ray D. Page, J...> ;Annals of Oncology. 2018 Nov 1
27 citations
Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non–Small-Cell Lung C...
Heather A. Wakelee, Zanete Zvirbule, Filippo de Braud, C. Daniel Kingsley, Tarek Mekhail, Thomas Lowe, Wolfgang Schütte, Hervé Lena, William E. Lawler, Fadi Braiteh, T...> ;Clinical Lung Cancer. 2017 Jan 1
24 citations
Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non-Small...
Fred R. Hirsch, Ramaswamy Govindan, Zanete Zvirbule, Fadi Braiteh, Achim Rittmeyer, Cristobal Belda-Iniesta, Dolores Isla, Thomas Cosgriff, Michelle Boyer, Masamichi U...> ;Clinical Lung Cancer. 2017 Jan 1
30 citations
Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4)
Robert J. Motzer, Anna Alyasova, Dingwei Ye, Andrey Karpenko, Hanzhong Li, Boris Alekseev, Liping Xie, G. Kurteva, Ruben Dario Kowalyszyn, Oleg Karyakin, Y. Neron, Tho...> ;Annals of Oncology. 2016 Mar 1
305 citations
Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With ...
Robert J. Motzer, Carlos H. Barrios, Tae Min Kim, Silvia Falcon, Thomas Cosgriff, W. Graydon Harker, Vichien Srimuninnimit, Ken Pittman, Roberto Sabbatini, Sun Young R...> ;Journal of Clinical Oncology. 2014 Sep 1
51 citations
A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer.
Barry Mirtsching, Thomas Cosgriff, Graydon Harker, Mark Keaton, Tarek Chidiac, Myo Min> ;Clinical Breast Cancer. 2011 Apr 1
18 citations
A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer.
Ralph V. Boccia, Thomas M. Cosgriff, David L. Headley, Suprith Badarinath, Shaker R. Dakhil> ;Clinical Colorectal Cancer. 2010 Apr 1
213 citations
Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic Syndromes
Roger M. Lyons, Thomas Cosgriff, Sanjiv Modi, Robert H. Gersh, John D. Hainsworth, Allen Lee Cohn, Heidi McIntyre, Indra J. Fernando, Jay Backstrom, C.L. Beach> ;Journal of Clinical Oncology. 2009 Apr 10
60 citations
Experience with intravenous ribavirin in the treatment of hemorrhagic fever with renal syndrome in Korea.
Janice M. Rusnak, William R. Byrne, Kyung N. Chung, Paul H. Gibbs, Theodore T. Kim, Ellen F. Boudreau, Thomas M. Cosgriff, Philip Pittman, Katie Y. Kim, Marianne S. Er...> ;Antiviral Research. 2009 Jan 1
Single-agent nab-paclitaxel given weekly (3/4) as first-line therapy for metastatic breast cancer (an International Oncology Network study, #I-04-012).
Mirtsching B, Cosgriff T, Harker G, Keaton M, Chidiac T, Min M> ;J. Clin. Oncol.. 2008-05-20
12 citations
A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplati...
Roger B. Cohen, Corey J. Langer, George R. Simon, Peter D. Eisenberg, John D. Hainsworth, Stefan Madajewicz, Thomas Michael Cosgriff, Kristen J. Pierce, Huiping Xu, K....> ;Cancer Chemotherapy and Pharmacology. 2007 Jun 1
First-line treatment of metastatic breast cancer with weekly abraxane (nab-paclitaxel: a 130 nm albumin-bound paclitaxel particle): A preliminary analysis of the phase...
Mirtsching B, Chidiac T, Cosgriff T> ;J. Clin. Oncol.. 2006-06-20
Cetuximab + FOLFOX6 as first line therapy for metastatic colorectal cancer (An International Oncology Network study, I-03-002).
Dakhil S, Cosgriff T, Headley D, Boccia RV, Badarinath S> ;J. Clin. Oncol.. 2006-06-20
Tranfusion independence assessed using three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.
Anthony S, Lyons R, Cosgriff T, Modi S> ;J. Clin. Oncol.. 2006-06-20
Cetuximab + FOLFOX 6 as first line therapy for metastatic colorectal cancer.
Scott J, Dakhil S, Cosgriff T, Pink C, Butler B, Boccia RV> ;J. Clin. Oncol.. 2005-06-01
Dose escalation study of pivanex (a histone deacetylase inhibitor) in combination with docetaxel for advanced non-small cell lung cancer.
Reid T, Weeks A, Vakil M, Cosgriff T, Harper T, Valone F, Magnuson D, Bhatnagar A> ;J. Clin. Oncol.. 2004-07-15
72 citations
Hemorrhagic fever virus-induced changes in hemostasis and vascular biology.
James Chen, Thomas M. Cosgriff> ;Blood Coagulation & Fibrinolysis. 2000 Jul 1
1 citations
Rhesus differential susceptibility to endotoxin is not associated with activation of plasma prekallikrein.
Dulce Veloso, Joseph I. Smith, Thomas M. Cosgriff> ;Immunopharmacology. 1999 Sep 1
11 citations
Successful treatment of severe refractory idiopathic thrombocytopenic purpura with liposomal doxorubicin
Thomas Cosgriff, Marcus L. Black, William Stein> ;American Journal of Hematology. 1998 Jan 1
7 citations
Primary T-cell lymphoma of muscle in a patient infected with human immunodeficiency virus
George H. Lum, Thomas M. Cosgriff, Russell Byrne, Vishnu Reddy> ;The American Journal of Medicine. 1993 Nov 1
5 citations
Structure, kinetics, and function of human and rhesus plasma prekallikreins are similar.
Dulce Veloso, Joseph I Smith, Stephen Denny, Thomas M. Cosgriff> ;Thrombosis and Haemostasis. 1992 Nov 10
251 citations
Prospective, Double-Blind, Concurrent, Placebo-Controlled Clinical Trial of Intravenous Ribavirin Therapy of Hemorrhagic Fever with Renal Syndrome
John W. Huggins, Chin Min Hsiang, Thomas M. Cosgriff, Mei Ying Guang, Joseph I. Smith, Zhen Ou Wu, James W. LeDuc, Zhi-Ming Zheng, J M Meegan, Qi Nan Wang, Dwayne D. O...> ;The Journal of Infectious Diseases. 1991 Dec 1
18 citations
Platelet dysfunction contributes to the haemostatic defect in haemorrhagic fever with renal syndrome.
Thomas M. Cosgriff, Ho Wang Lee, Anthony F. See, David B. Parrish, Jung Sik Moon, Dai Jung Kim, Richard M. Lewis> ;Transactions of the Royal Society of Tropical Medicine and Hygiene. 1991 Sep 1
13 citations
Changes in populations of immune effector cells during the course of haemorrhagic fever with renal syndrome
Richard M. Lewis, Ho Wang Lee, Anthony F. See, David B. Parrish, Jung Sik Moon, Dai Jung Kim, Thomas M. Cosgriff> ;Transactions of the Royal Society of Tropical Medicine and Hygiene. 1991 Jan 1
8 citations
Pulmonary edema in falciparum malaria. Slaying the dragon of volume overload.
Thomas M. Cosgriff> ;Chest. 1990 Jul 1
Join now to see all

Hospital Affiliations

East Jefferson General HospitalMetairie, Louisiana
St. Tammany Health SystemCovington, Louisiana